NCT04323748View on ClinicalTrials.gov

Dose Dense Rituximab for High Risk Newly Diagnosed Acute Immune Thrombocytopenic Purpura

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

February 24, 2021

Primary Completion Date

July 31, 2024

Study Completion Date

July 31, 2025

Conditions

Immune Thrombocytopenic Purpura

Interventions

DRUG

rituxan

"The dose dense administration of rituximab will consist of 5 doses total~Days: 0, 2, 7 (± 2 days), 14 (± 2 days), and 21 (± 2 days); Dose: 375 mg/m2"

Trial Locations (1)

10595

RECRUITING

New York Medical College, Valhalla